Docetaxel and Cyclophosphamide versus an Anthracycline-Based Chemotherapy as Treatment for HER2-Negative Breast Cancer
The purpose of this study is to determine if the docetaxel and cyclophosphamide (Taxotere; and Cytoxan;) chemotherapy regimen is as good as the anthracycline-based chemotherapy regimen (that is, a regimen that includes doxorubicin), the specific regimen is the doctor' choice. The primary objective is to determine which treatment works better based on how long it takes for breast cancer to come back, if ever. The study will enroll 1,843 female participants from many cancer centers in the US. In addition to other conditions for enrollment, there is no evidence of cancer after surgery to remove the breast cancer, and the surgery was within the past 84 days. Radiation therapy has to be completed at the time of study enrollment. Eligible patients had at least one positive lymph node but no evidence of cancer that has spread beyond the breast or lymph nodes. Patients with inflammatory breast cancer are not eligible.